comparemela.com

Latest Breaking News On - Small molecules - Page 6 : comparemela.com

Marla Dubinsky, MD: The Importance of Head-to-Head Trials in IBD

Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.

A-marla-dubinsky
Marla-dubinsky
Mount-sinai-kravis-children
Clinical-outcomes
Risankizumab-versus-ustekinumab
Guide-use
Small-molecules
Inflammatory-bowel

AgPlenus Announces Licensing Collaboration Agreement With Bayer To Develop A New Sustainable Weed Control Solution

AgPlenus Announces Licensing Collaboration Agreement With Bayer To Develop A New Sustainable Weed Control Solution
foodonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foodonline.com Daily Mail and Mail on Sunday newspapers.

Bayer-cropkey
Rehovot-prnewswire
Rachel-rama
Lavie-bio
Evogene-ltd
Agplenus-ltd
Bayer-ag
Nasdaq
Plenus-ltd
Crop-science
Small-molecules
Brian-ember

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution

The collaboration will tap into the potential of artificial intelligence to design and optimize crop protection chemistry, developing a novel sustainable Mode-of-Action broad-spectrum herbicide.

Israel
Rehovot
Hamerkaz
Rachel-pomerantz-gerber
Bayer-cropkey
Lavie-bio
Rachel-rama
Agplenus-ltd
Evogene-ltd
Nasdaq
Bayer-ag
Prnewswire-agplenus-ltd

Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke

Researchers utilized an untargeted metabolomics technique to look for new compounds and pathways that may contribute to residual cardiovascular disease risk.

Dragana-gordic-shutterstock
Nature-medicine
Heart
Ortality
Stroke
Analyte
Cardiovascular-disease
Enetic
N-vivo
Inflammation
Mass-spectrometry

Canada Pharmaceutical Market Share Projected to Reach USD 88.11 Billion By 2032, Growing at 6.9% CAGR: Polaris Market Research

The Canada pharmaceutical market size and share is currently valued at USD 48.62 billion in 2023. It is anticipated to generate an estimated revenue of USD 88.11 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 6.9% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024-2032. The key market players include AbbVie, AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson,

United-states
Canada
New-york
Canadians
Canadian
Eli-lilly
Route-of-administration
Astrazeneca
Abbvie-inc
Canadian-cancer-society
Roche-ltd
Johnson

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.